Looks like excellent results to me. The slope of the curves suggests that there would be continued improvement after 12 weeks, perhaps indicating that this will be a somewhat better drug than Pfizer's from an efficacy perspective.
Not hitting JAK3 has always been touted by INCY as a safety advantage, but there just isn't enough data here to see whether that claim is valid or not.
Market Data 
Markets 
AI
